Taiwan · Delayed Price · Currency is TWD Gwo Xi Stem Cell Applied Technology Co. , Company Description
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs.
The company’s products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke.
It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes.
The company was founded in 2011 and is based in Zhubei, Taiwan.
| Country | Taiwan |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Chuan-Feng Chiu |
Contact Details
Address: Building D Zhubei, 30261 Taiwan | |
| Phone | 886 3 658 5959 |
| Website | gwoxi.com.tw |
Stock Details
| Ticker Symbol | 6704 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006704000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Chuan-Feng Chiu | Chief Executive Officer |
| Bangyu LI | Accounting Supervisor |
| Po-Cheng Lin | Chief Technology Officer |